Elizabeth Woodworth provided evidence to government epidemiologists for 25 years.
In this interview she discusses early treatment of people with CV19 to maintain
their health and hopefully prevent hospitalization. As of Oct. 20, the U.S.
National Institute of Health recommends NO outpatient therapy. So either people
go into the hospital for treatment OR they get no treatment whatsoever.
Doctors world-wide who have been using Hydroxychloroquine and other medicines as
an early treatment for CV19 are creating their own treatment protocols to help
their patients recover more quickly - with fewer symptoms - and no need for
hospitalization.
In Canada we are following the U.S. guidelines with very limited treatment for
CV19 outside of hospitals.
The U.S. Centre for Disease Control said in 2017: Hydroxychloroquine can be
used by adults including pregnant women, and children of all ages. The only
proviso was people with psoriasis should not use it.
Countries using Hydroxychloroquine (HCQ) are showing lower - even much lower -
case fatality rates than countries like Canada and the US where it not being
'officially' used. According to the doctors using it, this is because the
treatments work.
The U.S. FDA (Food and Drug Administration) has warned against the outpatient
use of HCQ. The FDA gets 30% of its funding from the pharmaceutical industry.
Yale epidemiologist Dr. Harvey Risch said recently: Many or most of the 220,000
deaths in the US to date could have been prevented by widespread HCQ use THAT
THE FDA BLOCKED.
An Oct. 26 study released by four American doctors states: Outpatients at risk
of CV19 treated early with low-does HCQ and zinc had much lower hospitalizations
and death.